Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC)
Name:
Ramalingam.pdf
Size:
101.0Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
Ramalingam, S. S.Ahn, M. J.
Akamatsu, H.
Blackhall, Fiona H
Borghaei, H.
Hummel, H. D.
Johnson, M.
Reck, M.
Zhang, Y.
Jandial, D.
Cheng, S.
Paz-Ares, L.
Issue Date
2022
Metadata
Show full item recordCitation
Ramalingam SS, Ahn MJ, Akamatsu H, Blackhall F, Borghaei H, Hummel HD, et al. Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC). Annals of Oncology. 2022;33:S103-S4.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.02.186Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.02.186Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.02.186